A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Lowdose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)

Project: Research

Project Details

Project Description

NMA HREC Reference Number: SVHM HREC ref 020/20
NMA SSA Reference Number: SSA/59714/MonH-2020-227895(v2)
Monash Health Reference: RES-20-0000-601X
StatusActive
Effective start/end date16/09/20 → 15/09/25

Keywords

  • clinical trial
  • phase 3 study
  • treatment efficacy
  • treatment safety
  • Myeloma